Evidence map›Paper›PMID 28185222›Full record

ArticleInfection2017

Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.

Rita Murri, Barbara Fiori, Teresa Spanu, Ilaria Mastrorosa, Francesca Giovannenze, Francesco Taccari, Claudia Palazzolo, Giancarlo Scoppettuolo, Giulio Ventura, Maurizio Sanguinetti and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. In vitro antimicrobial activity and clinical use of trimethoprim-sulfamethoxazole for infections due to KPC-producing Gram-negative pathogens: a review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Antimicrobial resistance patterns ofVeterinary world · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. How to manage KPC infections.Therapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Rita MurriDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy. ritamurri@rm.unicatt.it.
Barbara FioriDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Teresa SpanuDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Ilaria MastrorosaDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Francesca GiovannenzeDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Francesco TaccariDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Claudia PalazzoloDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Giancarlo ScoppettuoloDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Giulio VenturaDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Maurizio SanguinettiDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Roberto CaudaDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Massimo FantoniDepartment of Infectious Diseases, Department of Microbiology, Catholic University of Rome, Rome, Italy.
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of the study was to evaluate the efficacy and tolerability of trimethoprim-sulfamethoxazole (also known as co-trimoxazole, TMPS) to treat Klebsiella pneumoniae (Kp)-K. pneumoniae carbapenemase (KPC) infections.

methodsClinical data of patients with a TMPS-susceptible Kp-KPC infection were collected as a case series.

resultsWe report clinical outcomes and tolerability for 14 patients infected by Kp-KPC strains susceptible to TMPS, including three bloodstream infections. In ten cases (71.4%), TMPS was administered as monotherapy. In all but one case, Kp-KPC infection was cured. In the remaining patient, therapy was discontinued because of an adverse event.

conclusionsThe use of TMPS to treat TMPS-susceptible Kp-KPC infections seems promising.

Indexed as

AgedAged, 80 and overAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesDrug-Related Side Effects and Adverse ReactionsFemaleHumansKlebsiella InfectionsKlebsiella pneumoniaeMaleMiddle AgedRetrospective StudiesTreatment OutcomeTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseTrimethoprim, Sulfamethoxazole Drug CombinationCarbapenemaseCo-trimoxazoleKPCMultidrug-resistant infectionsTrimethoprim–sulfamethoxazole

Identifiers

PMID28185222
OpenAlexW2586078522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.